Luminetics Product Line Training
Comprehensive training and support for LumineticsCore technology
Service · OtherCompany source
Company profile
About Digital Diagnostics
Digital Diagnostics is a pioneering AI diagnostic healthcare technology company committed to transforming healthcare quality, accessibility, and affordability worldwide. The company made history as the first to receive FDA clearance for an autonomous AI diagnostic platform that makes diagnoses without physician input. Their flagship product, LumineticsCore, is an AI diagnostic system that autonomously diagnoses diabetic retinopathy (including macular edema) in patients with diabetes at the point-of-care. The system uses a fundus camera to capture retinal images, which are then analyzed by the AI algorithm within 30 seconds to provide diagnostic results without requiring specialist overread or telemedicine callbacks. LumineticsCore is reimbursable using CPT code 92229 and helps close care gaps for diabetes eye exams, improving HEDIS and MIPS scores and Stars ratings. The company's approach to AI is built on an ethical foundation, with the system modeled to make decisions based on the same clinical disease detectors that eye care specialists would use. Digital Diagnostics serves front-line care providers, ophthalmologists, optometrists, payors, and patients, helping to prevent vision loss and blindness through early detection while improving healthcare efficiency and access to care.
Company description Digital Diagnostics official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Digital Diagnostics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Diabetic macular edema
- Diabetic retinopathy
Who it serves
- Community health centers
- Health systems
- Ophthalmologists
- Optometrists
- Payers
- Primary care providers
Deployment & integration
Cloud Saas · Other deployment with recorded integration context.
Recorded integration context: Epic.
Geographic context
MarketsGlobal · United States
Company sourceOfficial website
Company milestones
Platform expansion
First FDA clearance for autonomous AI diagnostic platform. Multiple successful deployments across health systems. Reimbursement established with CPT code 92229.
Partnerships
Recorded partners
- AbsoluteCare Healthcare System
- Cahaba Medical Care
- Johns Creek Primary Care
- OSF Healthcare
- Tarzana Treatment Centers
- University Medical Center
- Urban Health
- Zufall Health
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
LumineticsCore
FDA-cleared AI that autonomously diagnoses diabetic retinopathy at the point-of-care without physician input
Software · Cloud SaaSCompany source
SphereDx
Securely hosted diagnostic results platform built for Digital Diagnostics systems
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Neuroretinal Layer Thinning on OCT Imaging and Hemoglobin A1c in Youth With Type 1 Diabetes.JAMA ophthalmology · Jun 25, 2026
Diabetic retinal disease cure accelerator: Modernizing staging and endpoints.Progress in retinal and eye research · May 21, 2026
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.Cancer gene therapy · Jun 1, 2025
Cost-effectiveness of AI for pediatric diabetic eye exams from a health system perspective.NPJ digital medicine · Jan 2, 2025
Mitigation of AI adoption bias through an improved autonomous AI system for diabetic retinal disease.NPJ digital medicine · Dec 19, 2024
Expert-level detection of M-proteins in serum protein electrophoresis using machine learning.Clinical chemistry and laboratory medicine · Nov 26, 2024
Clinical validation
Clinical-trial records
Leveraging Artificial Intelligence to Prevent Vision Loss From DiabetesNCT06763952 · Mentioned · NOT YET RECRUITING
Telemedicine Self-examination of Speech and Memory for Rapid Detection of Cognitive Impairments Using Machine Learning MethodsNCT07558785 · Mentioned · ENROLLING BY INVITATION
Development of Digital Services for Parkinson's DiseaseNCT06733077 · Mentioned · RECRUITING
Camera Qualification StudyNCT05808699 · Sponsor · ACTIVE NOT RECRUITING
Digital Diagnostics and Intervention Services for Parkinson's DiseaseNCT06534177 · Mentioned · NOT YET RECRUITING
RAE (Realize, Analyze, Engage)NCT05227339 · Mentioned · COMPLETED
Regulatory
Regulatory records
IDx-DR v2.3K213037 · 510k · Jun 17, 2022
IDx-DRK203629 · 510k · Jun 10, 2021
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
91% reduction in unnecessary specialty visits
Pivotal clinical trial
Adherence rates increased from 16.2% to 50.7%
Johns Creek Primary Care case study
1 in 3 patients diagnosed with diabetic retinopathy
Cahaba Medical Care within 90 days
60% over target for annual eye exams
Urban Health case study
Reduction in time-to-follow-up from 60 days to 5 days
Tarzana Treatment Centers
Over 60,000 people prevented from going blind annually
Diabetic retinopathy prevention
$5B+ annual savings potential
100% compliance for diabetic retinopathy exams
AbsoluteCare Healthcare System
Streamline care during wellness checks and preserve vision for people living with diabetes
Allowed providers to effectively determine if a patient needed follow-up care during wellness visits
Cahaba Medical Care
Address health equity and detect diabetic retinopathy in high-risk patient population
Within 90 days, diagnosed one out of every three people tested with diabetic retinopathy
Johns Creek Primary Care
Increase diabetic retinopathy screening adherence rates in primary care setting
Adherence rates with diabetic retinal exams increased from 16.2% to 50.7% year over year
OSF Healthcare
Early detection of diabetic retinopathy changes not visible to human eye
Nearly one-quarter of all patients with diabetes tested positive for diabetic retinopathy
Tarzana Treatment Centers
Improve rates of annual eye exams and reduce time-to-follow-up in complex patient population
Reduced time-to-follow-up from 60 days with remote reading network to 5 days with LumineticsCore
University Medical Center (UMC)
Improve efficiency of diabetic eye exam screening process
More efficient system that allows for more exams to be conducted
Urban Health Plan (UHP)
Exceed quality targets for eye exams for diabetes and improve provider efficiency
Went from 40% below target of 1000 annual eye exams to 60% over target after implementation
Zufall Health
Provide crucial feedback for diabetes care intensification through organ damage identification
Identification of organ damage provided feedback for intensifying diabetes care
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Michael Abramoff
Founder
06 · Company updates
Updates from Digital Diagnostics
Recent articles published on Digital Diagnostics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.